Arrowhead Pharmaceuticals (NASDAQ: ARWR), a company that focuses on the treatment of intractable diseases by targeting the genes that cause them, has seen its stock rise by over 30% over the last month. The company currently has a pipeline of 9 drugs under clinical trials. Two (one Hepatitis B and another undisclosed drug) are licensed to Janssen Pharmaceuticals- and one (Cardiovascular drug) is licensed to Amgen. During its Q3 FY’19 earnings call conducted in August (FY ends September 30th), the company indicated the company has seen some positive developments relating to the Cardiovascular drug and the Hepatitis B drug, allowing it to collect milestone payments from its partners, boosting revenues.
We âstep backâ from these recent swings to review Arrowhead PharmaceuticalsÂ performance over the last few years, as a context for what might come next. Our Interactive dashboard, Why Is Arrowhead Pharmaceuticals Up Over 30% Over The Last Month? reviews the near term reasons and the big picture.
The context for the last few years:
A closer look At Arrowhead Pharmaceuticals’ Total Revenues over the last few years and the outlookÂ
Revenue for Arrowhead Pharmaceuticals decreased from $31.4 Mil in 2017 to $16.1 Mil in 2018; a -48.6% decrease.
This compares with Revenue growth of:
â¢ -58.6% in 2016
â¢ 19777.8% in 2017
We expect Revenue Growth to be 922% in 2019, driven by milestone payments from the company’s collaboration agreements with Janssen and Amgen.
A closer look At Arrowhead Pharmaceuticals’ Total ExpensesÂ over the last few years and the outlook
Total Expense for Arrowhead Pharmaceuticals increased from $67.5 Mil in 2017 to $71.6 Mil in 2018 – a increase of 6.1%.
This compares with Total Expense growth of:
â¢ -12.1% in 2016
â¢ -17.9% in 2017
We expect Total Expense to grow by 31.2% in 2019.
How does Arrowhead Pharmaceuticals’ Revenue Growth compare with rivals?
For more details on how Arrowhead Pharmaceuticals’ revenue growth compares with rivals, view our interactive dashboard analysis.
How hasÂ Arrowhead Pharmaceuticals’ EBT trended?
Earnings Before Taxes (EBT) for Arrowhead Pharmaceuticals decreased from $-34.4 Mil in 2017 to $-54.4 Mil in 2018 – a decrease of 58.4%.
This compares with EBT growth of:
â¢ -11.1% in 2016
â¢ -57.9% in 2017
We expect EBT to grow to about $72 million in 2019.
How has Arrowhead Pharmaceuticals’ Net Income and EPS trended?
For more information onÂ Arrowhead Pharmaceuticals’ Net Income and EPS, view our interactive dashboard analysis.
Whatâs behind Trefis? See How itâs Powering New Collaboration and What-Ifs
ForÂ CFOs and Finance TeamsÂ |Â Product, R&D, and Marketing Teams
More Trefis Data
Like our charts? ExploreÂ example interactive dashboardsÂ and create your own.